Edgar Snyder & Associates®
A Law Firm Representing Injured People
Call Us Toll Free 24/7
Published on Sep 13, 2006 by Edgar Snyder

Is Arcoxia the Next Vioxx?


An arthritis drug Merck developed to replace Vioxx and compete with Celebrex may be just as dangerous, according to a whistle-blower from the Food & Drug Administration. In an editorial published in the Journal of American Medical Association website, David Graham, a physician in the FDA Office of Drug Safety, writes the FDA should use common sense before willfully accepting disinformation masked as evidence about the drug.

In a report by Merck, Arcoxia is said to have similar cardiovascular events as diclofenac, an older arthritis drug. This raises serious concern because collective research results report that diclofenac increased cardiovascular risks as much as lower-dose Vioxx. The only riskier COX-2 was high dose Vioxx.

Arcoxia is a COX-2 inhibitor, like Vioxx and Celebrex. Only a month after Vioxx was removed from the market, the FDA issued an “approvable letter” and asked for more data about Arcoxia’s safety and effectiveness. The FDA has not made a final decision about Arcoxia but the drug is already sold in 62 countries.

Source: “FDA Whistle-blower Graham Blasts New Merck Arthritis Drug.” By Rita Rubin. USA Today. September 13, 2006.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio, and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
Briefly describe your injuries

Recent News

Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Sep 16, 2016
New CDC Tool Will Help Keep Traveling Workers Safe
Sep 14, 2016
PA Residents: You're This Much More Likely to Hit a Deer